

This document has been translated from a Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. RaQualia Pharma Inc. assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Securities code: 4579  
March 25, 2022

Hirobumi Takeuchi  
Representative Director  
**RaQualia Pharma Inc.**  
1-21-19 Meieki Minami,  
Nakamura-ku, Nagoya, Japan

## NOTICE OF RESOLUTIONS AT THE 14TH ORDINARY GENERAL MEETING OF SHAREHOLDERS

Dear Shareholders:

We hereby inform you that the following matters were reported and resolved at the 14th Ordinary General Meeting of Shareholders of RaQualia Pharma Inc. (the "Company") held on March 25, 2022.

- Report matters:**
1. The Business Report and the Consolidated Financial Statements for the 14th Fiscal Year (January 1, 2021 to December 31, 2021), and the results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit and Supervisory Committee
  2. Non-consolidated Financial Statements for the 14th Fiscal Year (January 1, 2021 to December 31, 2021)

We reported on the content of 1 and 2 above.

**Resolution matters:**

**Proposal 1:**

**Partial Amendment to the Articles of Incorporation**

This proposal was approved and adopted as proposed. As the revised provisions stipulated in the proviso of Article 1 of the Supplementary Provisions of the "Act for Partial Revision of the Companies Act" (Act No. 70 of 2019) will come into effect on September 1, 2022, the Company amended the Articles of Incorporation of the Company in preparation for the introduction of a system to electronically provide materials for general meetings of shareholders.

**Proposal 2:**

**Election of Four (4) Directors (excluding Directors Serving on the Audit and Supervisory Committee)**

This proposal was approved and adopted as proposed, and Mr. Hirobumi Takeuchi and Mr. Michihiro Tsuchiya were reelected, and Mr. Masaki Sudo and Mr. Katsuhiko Uto were newly elected as Directors (excluding Directors serving on the Audit and Supervisory Committee), and each assumed office. Mr. Michihiro Tsuchiya is an Outside Director.

**Proposal 3:**

**Presentation of Retirement Allowance to Retiring Directors**

This proposal was approved and adopted as proposed. To reward Mr. Shuzo Watanabe for his service during his term of office, it was determined that the Company shall present him with a retirement allowance of 17,800,000 yen and that the timing and method for the presentation be left to the discretion of the Board of Directors.

**Proposal 4:****Determination of Remuneration for Granting Shares with Transfer Restrictions and Performance-linked Shares for Subsequent Delivery to Directors (Excluding Directors Serving on the Audit and Supervisory Committee and Outside Directors)**

This proposal was approved and adopted as proposed, and the Company established a restricted stock-based compensation plan and a post-delivery type performance-linked stock to Directors (excluding Directors serving on the Audit and Supervisory Committee and Outside Directors).

**About the Company's Officer System**

By a resolution passed at the meeting of the Board of Directors that was held after the General Meeting, the Company's Director system on and after March 25, 2022, was decided as follows.

Representative Director	Hirobumi Takeuchi
Director (Outside Director)	Michihiro Tsuchiya
Director	Masaki Sudo
Director	Katsuhiko Uto
Audit and Supervisory Committee Member (Outside Director)	Kosuke Ishii
Audit and Supervisory Committee Member (Outside Director)	Yuichi Kakinuma
Audit and Supervisory Committee Member (Outside Director)	Megumi Uzu